ALKS vs HRMY: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ALKS is the larger of the two ($7.66B market cap): the incumbent the market prices for continued execution (33.70x forward earnings, beta 0.23). HRMY is the smaller challenger ($1.96B), cheaper on forward earnings (5.49x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

ALKS vs HRMY: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricALKSHRMYWhat it tells you
Market cap$7.66B$1.96BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E33.705.49Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.230.98Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range65% of range42% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book4.111.82How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: HRMY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ALKS and HRMY affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALKS and HRMY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALKS and HRMY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Alkermes plc (ALKS) do?

Alkermes plc is an Ireland-domiciled, Nasdaq-listed biopharmaceutical company focused on the central nervous system. Its commercial base spans Vivitrol (extended-release naltrexone for alcohol and opioid dependence), Aristada (long-acting injectable for schizophrenia), and Lybalvi (an oral olanzapine/samidorphan combination for schizophrenia and bipolar I). In February 2026 it acquired Avadel Pharmaceuticals, adding Lumryz, a once-nightly sodium oxybate for narcolepsy, which broadened the portfolio into sleep medicine. The company is profitable on an adjusted basis and generates meaningful operating cash flow, which it uses to fund its pipeline rather than relying heavily on dilution.

Full ALKS guide

What does Harmony Biosciences Holdings, Inc. (HRMY) do?

Harmony Biosciences Holdings is a commercial-stage neuroscience company based in Plymouth Meeting, Pennsylvania, that licensed pitolisant from the French firm Bioprojet in 2017 and brought it to the U.S. market as WAKIX in 2019. WAKIX is a histamine H3 receptor antagonist and inverse agonist, and it is the only FDA-approved narcolepsy treatment that is not a scheduled controlled substance, which matters commercially because prescribers and patients avoid the paperwork and stigma attached to oxybate and stimulant options. Approvals have widened over time: excessive daytime sleepiness in adults in 2019, cataplexy in adults in 2020, and pediatric patients aged six and up in 2024 and 2026. The company reports a single segment, sells only in the United States, and had roughly 8,950 average patients on therapy in the second quarter of 2026 against a U.S. diagnosed narcolepsy population it estimates at about 80,000.

Full HRMY guide

ALKS vs HRMY: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • ALKS drivers: Orexin pipeline optionality; Cash-generative commercial base.
  • HRMY drivers: WAKIX is still accelerating in year seven; The pitolisant franchise extension is the answer to 2030.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. For HRMY, one product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical.

ALKS or HRMY: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALKS if you believe its drivers more; HRMY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALKS and HRMY guides.

ALKS vs HRMY: the full fundamentals

ALKS. Lumryz consolidation lifted revenue sharply in 2026, but deal costs and interest kept GAAP earnings thin, so the trailing P/E above 100x says little; on forward estimates the stock trades near 23 times earnings and about 4 times sales. The market cap has fallen to roughly $6.9 billion from about $8.5 billion in July, though the shares remain up about 45% for 2026. The 18 analysts tracked by Yahoo Finance had a mean target near $56 as of October 16, 2026.

HRMY. Netting out the balance sheet leaves an enterprise value near $1.4B against ~$960M of trailing revenue and ~$181M of net income, roughly 1.5 times sales for a business growing 30%, and the forward multiple of about 5.5 times 2027 estimates is lower still. The discount is the price of one product with a 2030 expiry date, a live patent case and a CEO change. The first late-stage pipeline readouts do not arrive until 2027, so near-term moves are more likely to come from WAKIX quarters and the AET ruling.

Headline figures (approximate, October 2026): ALKS shows revenue (ttm) ~$1.67B, up ~27% YoY in Q2 2026, q2 2026 revenue ~$496M; adjusted EPS $0.70 vs $0.29 expected, net income (ttm) ~$66M GAAP (~4% net margin), margins (ttm) ~87% gross, ~16% operating; HRMY shows revenue (ttm) ~$960M, all from WAKIX, up ~30% year over year in Q2, net income (ttm) ~$181M (profit margin ~19%), diluted eps (ttm) ~$3.10, p/e ~12x trailing, ~5.5x on 2027 EPS estimate of ~$7.

The bottom line: ALKS vs HRMY

ALKS and HRMY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALKS and HRMY exposure against your real portfolio. It is not an investment adviser.

Wondering how ALKS or HRMY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Alkermes plc

Ask Walnut's AI anything about ALKS and see how it fits what you own.

FAQ

What is the difference between ALKS and HRMY?

+

Alkermes plc is an Ireland-domiciled, Nasdaq-listed biopharmaceutical company focused on the central nervous system. Harmony Biosciences Holdings is a commercial-stage neuroscience company based in Plymouth Meeting, Pennsylvania, that licensed pitolisant from the French firm Bioprojet in 2017 and brought it to the U.S. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ALKS or HRMY the better stock?

+

Neither is universally better. ALKS is the larger incumbent; HRMY is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ALKS or HRMY?

+

On forward P/E (as of November 2026), ALKS trades at 33.70x and HRMY at 5.49x, so HRMY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ALKS and HRMY?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ALKS vs HRMY?

+

ALKS: Clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. Legacy franchises face patent expiries and generic competition (notably Vivitrol and the schizophrenia injectables), which can erode the cash base that funds the pipeline. The Avadel deal added integration risk and litigation exposure tied to Lumryz's competitive position against Jazz Pharmaceuticals' oxybate products. Concentration in central-nervous-system and sleep indications leaves Alkermes exposed to specific payer, pricing, and regulatory dynamics, and as an Ireland-domiciled company it also carries tax and cross-border considerations. Any of these can drive outsized share-price swings around data and regulatory catalysts: the stock fell about 6% on what the company described as positive ADHD data in September 2026, and it was down about 23% over the three months to October 16. Balance-sheet leverage is also higher after the acquisition, and GAAP earnings are thin (trailing net income of about $66 million). HRMY: One product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical. The seventh filer, AET Pharma US, is still litigating in the District of Delaware; a bench trial concluded in February 2026, post-trial briefing is complete, and closing arguments are set for October 22, 2026, with an adverse ruling capable of pulling that date forward. Harmony and Novitium filed a separate infringement suit against AET and its marketing partner Sandoz in April 2026 over the amorphous pitolisant patent (case 26-cv-00453-JLH), and the defendants answered in June with antitrust counterclaims, which introduces a liability the company was not previously carrying. Competitively, the oral orexin agonists in late-stage development at Takeda and Alkermes target the underlying deficiency in narcolepsy type 1 rather than the symptom, and if they reach the market with strong efficacy they could compress WAKIX before its patents expire. Two smaller items also matter: gross margin fell from 81.0% to 75.8% year over year on new Novitium royalties, and leadership is in flux, with the CFO having departed in July 2026 (an interim officer is in place) and the CEO set to hand over on January 1, 2027. The CEO announcement on October 12 sent the shares sharply lower that day, and the stock is down ~8.6% over the past month.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALKS or HRMY; figures are approximate and dated (as of November 2026). Verify current data before investing.